Cargando…
Lipoprotein‐Associated Phospholipase A(2) Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease
BACKGROUND: We evaluated lipoprotein‐associated phospholipase A(2) (Lp‐PLA (2)) activity in patients with stable coronary heart disease before and during treatment with darapladib, a selective Lp‐PLA (2) inhibitor, in relation to outcomes and the effects of darapladib in the STABILITY trial. METHODS...
Ejemplares similares
-
Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long‐Term Ticagrelor in Stable Patients With Prior Myocardial Infarction
por: Magnani, Giulia, et al.
Publicado: (2021) -
Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS–TIMI 54
por: Bonaca, Marc P., et al.
Publicado: (2018) -
The Effect of Egg Consumption in Hyperlipidemic Subjects during Treatment with Lipid-Lowering Drugs
por: Klangjareonchai, Theerawut, et al.
Publicado: (2012) -
Long-term cost effectiveness of ticagrelor in patients with acute coronary syndromes in Thailand
por: Yamwong, Sukit, et al.
Publicado: (2014) -
Relationship of vitamin D status and bone mass according to vitamin D-binding protein genotypes
por: Nimitphong, Hataikarn, et al.
Publicado: (2015)